PLZF is a negative regulator of retinoic acid receptor transcriptional activity

Nuclear Receptor

Volumn 1, Issue , 2003, Pages

  Martin, Perrine J ^a   Delmotte, Marie Hélène ^b   Formstecher, Pierre ^a   Lefebvre, Philippe ^a  

^a INSERM   (France)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR ALPHA; GLUCOCORTICOID RECEPTOR; GLUTATHIONE TRANSFERASE; HYBRID PROTEIN; PROMYELOCYTIC LEUKEMIA PROTEIN; REGULATOR PROTEIN; RETINOIC ACID RECEPTOR; TRANSCRIPTION FACTOR; ZINC FINGER PROTEIN;

AMINO TERMINAL SEQUENCE; ARTICLE; BINDING AFFINITY; CHROMOSOME TRANSLOCATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DIMERIZATION; GENE OVEREXPRESSION; HEMATOPOIESIS; HUMAN; HUMAN CELL; IN VITRO STUDY; LIGAND BINDING; NONHUMAN; PROTEIN ANALYSIS; PROTEIN PROTEIN INTERACTION; RECEPTOR BINDING; RECEPTOR INTRINSIC ACTIVITY; REGULATORY MECHANISM; RHOMBENCEPHALON; TRANSCRIPTION REGULATION; TWO HYBRID SYSTEM; YEAST;

EID: 4344669923     PISSN: 14781336     EISSN: None     Source Type: Journal    
DOI: 10.1186/1478-1336-1-6     Document Type: Article

References (36)

1. Lefebvre P: Molecular basis for designing selective modulators of retinoic acid receptor transcriptional activities. Curr Drug Targets Immune Endocr Metabol Disord 2001, 1:153-164.
2. Rachez C, Freedman LP: Mediator complexes and transcription. Curr Opin Cell Biol 2001, 13:274-280.
3. Li X, Lopez-Guisa JM, Ninan N, Weiner EJ, Rauscher III FJ, Marmorstein R: Overexpression, purification, characterization, and crystallization of the BTB/POZ domain from the PLZF oncoprotein. J Biol Chem 1997, 272:27324-27329.
4. Lin RJ, Nagy L, Inoue S, Shao WL, Miller WH, Evans RM: Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature 1998, 391:811-814.
5. Grignani F, DeMatteis S, Nervi C, Tomassoni L, Gelmetti V, Cioce M, et al.: Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia. Nature 1998, 391:815-818.
6. Melnick AM, Westendorf JJ, Polinger A, Carlile GW, Arai S, Ball HJ, et al.: The ETO protein disrupted in t(8;21)-associated acute myeloid leukemia is a corepressor for the promyelocytic leukemia zinc finger protein. Mol Cell Biol 2000, 20:2075-2086.
7. Gelmetti V, Zhang J, Fanelli M, Minucci S, Pelicci PG, Lazar MA: Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO. Mol Cell Biol 1998, 18:7185-7191.
8. Ball HJ, Melnick A, Shaknovich R, Kohanski RA, Licht JD: The promyelocytic leukemia zinc finger (PLZF) protein binds DNA in a high molecular weight complex associated with cdc2 kinase. Nucl Acid Res 1999, 27:4106-4113.
9. Li JY, English MA, Ball HJ, Yeyati PL, Waxman S, Licht JD: Sequence-specific DNA binding and transcriptional regulation by the promyelocytic leukemia zinc finger protein. J Biol Chem 1997, 272:22447-22455.
10. Sitterlin D, Tiollais P, Transy C: The RAR alpha-PLZF chimera associated with Acute Promyelocytic Leukemia has retained a sequence-specific DNA-binding domain. Oncogene 1997, 14:1067-1074.
11. Koken MH, Reid A, Quignon F, Chelbi-Alix MK, Davies JM, Kabarowski JH, et al.: Leukemia-associated retinoic acid receptor alpha fusion partners, PML and PLZF, heterodimerize and colocalize to nuclear bodies. Proc Natl Acad Sci U S A 1997, 94:10255-10260.
12. Zhong S, Salomoni P, Pandolfi PP: The transcriptional role of PML and the nuclear body. Nat Cell Biol 2000, 2:E85-E90.
13. Shaknovich R, Yeyati PL, Ivins S, Melnick A, Lempert C, Waxman S, et al.: The promyelocytic leukemia zinc finger protein affects myeloid cell growth, differentiation, and apoptosis. Mol Cell Biol 1998, 18:5533-5545.
14. Barna M, Hawe N, Niswander L, Pandolfi PP: PLZF regulates limb and axial skeletal patterning. Nat Genet 2000, 25:166-172.
15. Chen SJ, Zelent A, Tong JH, Yu HQ, Wang ZY, Derre J, et al.: Rearrangements of the retinoic acid receptor alpha and promyelocytic leukemia zinc finger genes resulting from t(11;17)(q23;q21) in a patient with acute promyelocytic leukemia. J Clin Invest 1993, 91:2260-2267.
16. Chen Z, Guidez F, Rousselot P, Agadir A, Chen SJ, Wang ZY, et al.: PLZF-RAR alpha fusion proteins generated from the variant t(11;17) (q23;q21) translocation in acute promyelocytic leukemia inhibit ligand-dependent transactivation of wild-type retinoic acid receptors. Proc Natl Acad Sci U S A 1994, 91:1178-1182.
17. Licht JD, Chomienne C, Goy A, Chen A, Scott AA, Head DR, et al.: Clinical and molecular characterization of a rare syndrome of acute promyelocytic leukemia associated with translocation (11;17). Blood 1995, 85:1083-1094.
18. Licht JD, Shaknovich R, English MA, Melnick A, Li JY, Reddy JC, et al.: Reduced and altered DNA-binding and transcriptional properties of the PLZF-retinoic acid receptor-alpha chimera generated in t(11;17)-associated acute promyelocytic leukemia. Oncogene 1996, 12:323-336.
19. Guidez F, Huang W, Tong JH, Dubois C, Balitrand N, Waxman S, et al.: Poor response to all-trans retinoic acid therapy in a t(11;17) PLZF/RAR alpha patient. Leukemia 1994, 8:312-317.
20. Koken MH, Daniel MT, Gianni M, Zelent A, Licht J, Buzyn A, et al.: Retinoic acid, but not arsenic trioxide, degrades the PLZF/RARalpha fusion protein, without inducing terminal differentiation or apoptosis, in a RA-therapy resistant t(11;17)(q23;q21) APL patient. Oncogene 1999, 18:1113-1118.
21. Wang ZG, Delva L, Gaboli M, Rivi R, Giorgio M, CordonCardo C, et al.: Role of PML in cell growth and the retinoic acid pathway. Science 1998, 279:1547-1551.
22. Zhong S, Delva L, Rachez C, Cenciarelli C, Gandini D, Zhang H, et al.: A RA-dependent, tumour-growth suppressive transcription complex is the target of the PML-RARalpha and T18 oncoproteins. Nat Genet 1999, 23:287-295.
23. Doucas V, Tini M, Egan DA, Evans RM: Modulation of CREB binding protein function by the promyelocytic (PML) oncoprotein suggests a role for nuclear bodies in hormone signaling. Proc Natl Acad Sci U S A 1999, 96:2627-2632.
24. Renaud JP, Rochel N, Ruff M, Vivat V, Chambon P, Gronemeyer H, et al.: Crystal structure of the RAR-gamma ligand-binding domain bound to all-trans retinoic acid. Nature 1995, 378:681-689.
25. Bourguet W, Vivat V, Wurtz JM, Chambon P, Gronemeyer H, Moras D: Crystal structure of a heterodimeric complex of RAR and RXR ligand-binding domains. Mol Cell 2000, 5:289-298.
26. Mouchon A, Delmotte M-H, Formstecher P, Lefebvre P: Allosteric Regulation Of The Discriminative Responsiveness of Retinoic Acid Receptor to Natural and Synthetic Ligands By Retinoid X Receptor And DNA. Mol Cell Biol 1999, 19:3073-3085.
27. Depoix C, Delmotte MH, Formstecher P, Lefebvre P: Control of retinoic acid receptor heterodimerization by ligand-induced structural transitions. a novel mechanism of action for retinoid antagonists. J Biol Chem 2001, 276:9452-9459.
28. Ward JO, McConnell MJ, Carlile GW, Pandolfi PP, Licht JD, Freedman LP: The acute promyelocytic leukemia-associated protein, promyelocytic leukemia zinc finger, regulates 1,25-dihydroxyvitamin D(3)-induced monocytic differentiation of U937 cells through a physical interaction with vitamin D(3) receptor. Blood 2001, 98:3290-3300.
29. Dhordain P, Albagli O, Lin RJ, Ansieau S, Quief S, Leutz A, et al.: Corepressor SMRT binds the BTB/POZ repressing domain of the LAZ3/BCL6 oncoprotein. Proc Natl Acad Sci U S A 1997, 94:10762-10767.
30. Zhang T, Xiong H, Kan LX, Zhang CK, Jiao XF, Fu G, et al.: Genomic sequence, structural organization, molecular evolution, and aberrant rearrangement of promyelocytic leukemia zinc finger gene. Proc Natl Acad Sci U S A 1999, 96:11422-11427.
31. Lin B, Chen GQ, Xiao D, Kolluri SK, Cao X, Su H, et al.: Orphan receptor COUP-TF is required for induction of retinoic acid receptor beta, growth inhibition, and apoptosis by retinoic acid in cancer cells. Mol Cell Biol 2000, 20:957-970.
32. Gavalas A: ArRAnging the hindbrain. Trends in Neurosciences 2002, 25:61-64.
33. Delmotte MH, Tahayato A, Formstecher P, Lefebvre P: Serine 157, a retinoic acid receptor alpha residue phosphorylated by protein kinase C in vitro, is involved in RXR.RARalpha heterodimerization and transcriptional activity [In Process Citation]. J Biol Chem 1999, 274:38225-38231.
34. Perlmann T, Jansson L: A novel pathway for vitamin A signaling mediated by RXR heterodimerization with NGFI-B and NURR1. Genes Dev 1995, 9:769-782.
35. Collingwood TN, Butler A, Tone Y, Clifton-Bligh RJ, Parker MG, Chatterjee VKK: Thyroid hormone-mediated enhancement of heterodimer formation between thyroid hormone receptor beta and retinoid X receptor. J Biol Chem 1997, 272:13060-13065.
36. Lefebvre B, Mouchon A, Formstecher P, Lefebvre P: H11-H12 Loop Retinoic Acid Receptor Mutants Exhibit Distinct trans-Activating and trans-Repressing Activities in the Presence of Natural or Synthetic Retinoids. Biochemistry 1998, 37(26):9240-9249.